Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23115414 | 0.96 | MAOA (0.45) | CA12CA1CA2CA9MAOA | |
| SCHEMBL25189693 | 0.96 | CA12 (0.49) | CA12CA1CA2CA9MAOA | |
| SCHEMBL24654163 | 0.92 | MAOA (0.46) | CA12CA1CA2CA9MAOA | |
| SCHEMBL31065300 | 0.90 | CA12 (0.55) | CA12CA1CA2CA9MAOA | |
| SCHEMBL25204665 | 0.89 | CA12 (0.44) | CA12CA1CA2CA9MAOA | |
| SCHEMBL25239638 | 0.89 | CA12 (0.44) | CA12CA1CA2CA9MAOA | |
| SCHEMBL25201565 | 0.89 | CA12 (0.44) | CA12CA1CA2CA9MAOA | |
| SCHEMBL23115371 | 0.89 | MAOA (0.47) | CA12CA1CA2CA9MAOA | |
| SCHEMBL30976114 | 0.86 | CA12 (0.45) | CA12CA1CA2CA9MAOA | |
| SCHEMBL25181487 | 0.86 | CA12 (0.59) | CA12CA1CA2CA9MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312293-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20230286903-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230286903-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230286903-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| US-11597698-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-4031524-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-114728887-A | Branched tail end lipid compounds and compositions for intracellular delivery of therapeutic agents | 摩登纳特斯有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220106259-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-04-07 | — | — | US | disclosed |
| US-11066355-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066355-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210087135-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-03-25 | — | — | US | disclosed |
| US-20210087135-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-03-25 | — | — | US | disclosed |
| WO-2021055833-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055833-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286903-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | CA12 4770/4885CA1 4771/4885CA2 4841/4885 |
| US-11597698-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | PLTP, LNPK, PLIN3 | CA12 4770/4885CA1 4771/4885CA2 4841/4885 |
| US-12312293-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | PLTP, LNPK, PLIN3 | CA12 4770/4885CA1 4771/4885CA2 4841/4885 |
| US-11066355-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | PLTP, LNPK, PLIN3 | CA12 4770/4885CA1 4771/4885CA2 4841/4885 |
| US-20210087135-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | CA12 4770/4885CA1 4771/4885CA2 4841/4885 |
| US-20220106259-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | CA12 4770/4885CA1 4771/4885CA2 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.